SoureBio Executive Chairman, Jay LeCoque, discusses the key drivers to their five fold EBITDA growth

Jay covers the recent COVID testing agreements with the NHS and a major high street pharmacy as well as their partnership agreement with Oxford Nanopore. In addition Jay touches on future acquisition plans and the possibility of offering mobile testing.